Enthusiastic feed-back of nutraceutical industry at VENDORBRIEF presentation of Mythocondro® held last week during Supply Side West, in Las Vegas.

Results of a double-blind, placebo-controlled, human clinical trial showed that nearly one month of oral supplementation with Cognizin® citicoline resulted in improved attention and motor function in healthy adolescent males.

The results of a randomized, double-blind, placebo-controlled clinical trial showed that Cognizin® citicoline (Jarrow® Formulas) was effective at reducing cocaine use, based on urine drug screens, in patients with bipolar disorder and cocaine dependence.

A new randomized, double-blind, placebo-controlled, human clinical trial published in the Journal of the International Society of Sports Nutrition found, for the first time, that one week of daily oral supplementation with 200 mg of Setria® Glutathione and 2 grams of L-citrulline enhanced nitric oxide (NO) levels.

Cognizin® today released national survey data that sheds light on consumer concerns related to brain health and function.